Improving The Quantity, Quality, Relevance And Conduct Of Clinical Trials Of Medicines In Children.
Funder
National Health and Medical Research Council
Funding Amount
$102,576.00
Summary
I am a specialist clinical trials pharmacist focussed on the challenges associated with the conduct of medicinal trials in children. My intention is to collect evidence to determine the best strategies for improving the quantity, quality and relevance of clinical trials in children. This will help to ensure safe and effective age-appropriate drug therapies for children and improve the health outcomes of our children.
Extending The MIS BAIR Randomised Trial Of BCG To Prevent Childhood Allergy And Infection
Funder
National Health and Medical Research Council
Funding Amount
$939,504.00
Summary
BCG (used till recently to prevent tuberculosis) is a potential low cost and readily available vaccine which could reduce the rates of allergy and infection in Australian children. We propose to extend our existing NHMRC-funded trial, which studies whether BCG vaccinatinon given at birth prevents the development food allergy, eczema and infection in the 1st year of life, to see if this effect continues until 5yrs of age. At this age, we can also see if BCG vaccination at birth prevents asthma.
In Vitro And In Vivo Assessment Of The Funhaler -an Innovative Therapeutic Device For Children
Funder
National Health and Medical Research Council
Funding Amount
$472,750.00
Summary
Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler ....Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler incorporates a spinning toy attached to the outside of the spacer. The toy is activated when the patient breathes through the spacer. The device has been designed to encourage children to co-operate when their asthma therapy is being delivered. The Funhaler is currently in the late development stage. We propose, firstly, to carry out in vitro assessments of drug delivery from the Funhaler compared to the two most widely available small volume spacers: the Aerochamber Plus (Trudell, Canada) and the Breath-A-Tech (Scott-Dibben, Australia). These assessments will be carried out to meet the standards of regulatory bodies worldwide (including the FDA). Secondly, we propose to perform extensive in vivo studie: filter studies to assess drug delivery to the patient; deposition studies to measure drug deposition in the lungs; and a pilot clinical trial to assess the efficacy of the device during medium to long-term use in children aged 2-8 years.Read moreRead less
Reducing Vaccine Preventable Diseases In Children: Using National Active Hospital-based Surveillance To Evaluate And Improve Immunisation Program Performance
Funder
National Health and Medical Research Council
Funding Amount
$1,049,916.00
Summary
This proposal aims to evaluate and improve upon immunisation policy and programs for the prevention of severe childhood influenza and pertussis. Using our successful Paediatric Active Enhanced Disease Surveillance (PAEDS) network in 6 major children's hospitals across Australia, we will identify gaps in the evidence base needed to better control influenza and pertussis and in particular to ensure programs are delivered in such a way so as to address health inequalities.
Early Environmental Determinants Of Pancreatic Islet Autoimmunity: A Pregnancy To Early Life Cohort Study In Children At Risk Of Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$1,124,069.00
Summary
The doubling in incidence of type 1 diabetes in children over the last 20 years may be explained by our modern environment, including excessive weight gain in pregnancy and early life, inadequate dietary omega- 3 fatty acids or vitamin D, or viral infections. We therefore aim to study children with a family member with type 1 diabetes from the pregnancy and through early childhood to determine the effects of the environment on their risk of developing type 1 diabetes .This will lead to strategie ....The doubling in incidence of type 1 diabetes in children over the last 20 years may be explained by our modern environment, including excessive weight gain in pregnancy and early life, inadequate dietary omega- 3 fatty acids or vitamin D, or viral infections. We therefore aim to study children with a family member with type 1 diabetes from the pregnancy and through early childhood to determine the effects of the environment on their risk of developing type 1 diabetes .This will lead to strategies to prevent type 1 diabetes.Read moreRead less
Centre Of Research Excellence For The Protection Of Pancreatic Beta Cells
Funder
National Health and Medical Research Council
Funding Amount
$2,607,110.00
Summary
Type 1 diabetes (T1D) is an autoimmune disorder that results in the destruction of the pancreatic beta cells. The overall aim of the CRE is to elucidate the gene-environment interactions and modifiable environmental exposures that are driving the development of islet autoimmunity and progression to T1D. The CRE will unify and add value to new and established collaborations with multi-disciplinary input from genomics, bioinformatics and systems biology into the investigation of T1D.
Maternal Carriage Of Prevotella During Pregnancy Influences Offspring Innate Immune Responses And Asthma At Age 7
Funder
National Health and Medical Research Council
Funding Amount
$916,798.00
Summary
This project will investigate the relationship between the bacteria a mother carries in her gut during pregnancy and her baby’s risk of developing allergic disease and asthma. We will investigate underlying immune pathways and conduct experiments in mice to determine whether inoculating mothers with a specific type of bacteria known as Prevotella could be used to prevent food allergies and asthma in the offspring.
Prevention And Improved Management Of Paediatric Food Allergy
Funder
National Health and Medical Research Council
Funding Amount
$479,882.00
Summary
There is an urgent need to prevent food allergy and better manage its consequences. My research will identify: causes of food allergy (primary prevention); factors leading to adverse events in food allergic children (secondary prevention); and the role of food allergy in the ‘atopic march’ i.e. progression to other allergic conditions (tertiary prevention). The results of my research will be used to update policy and practice guidelines to change behaviour and improve clinical care.
Centre Of Research Excellence In Eradicating Food Allergy: Prevention, Cure And Reducing Adverse Events
Funder
National Health and Medical Research Council
Funding Amount
$2,496,041.00
Summary
Australia has the highest reported rate of food allergy in the world. We aim to eradicate food allergy through improved prevention and cure, supported by evidence generated by our collaborative network of research. In addition, we aim to help prevent children with food allergy having anaphylaxis through improved public health policy and clinical pathways. As a second wave of the allergy epidemic, we are well positioned to turn back the tide of this newly emergent health threat to the public.